Anatara Lifesciences Ltd
Anatara Lifesciences Ltd
Your view on ANR.AX
Overview
What the company does, where it operates, and who runs it.
About Anatara Lifesciences Ltd
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- David Lionel Brookes
- Headquarters
- 62 Lygon Street, Adelaide, SA, AU
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- David Lionel Brookes
- Headquarters
- 62 Lygon Street, Adelaide, SA, AU
Anatara Lifesciences Ltd is an Australian enterprise focused on researching, developing, and commercializing scientifically-validated therapies for digestive system ailments affecting both humans and animals. Its product portfolio includes Gastrointestinal ReProgramming (GRP), a proprietary blend combining bromelain with other evidence-based ingredients, specifically formulated to target the underlying issues of human gastrointestinal conditions such as irritable bowel syndrome and inflammatory bowel disease. The firm also offers 3FDC, designed to address anxiety, stress, or depression. In the animal health sector, Anatara provides Detach for treating diarrhea in piglets, BONIFF as an enhanced dry feed formulation for weaned piglets, and ANR-pf, a unique additive for poultry drinking water. This company was founded in 2010 and is headquartered in Carlton, Australia.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks the stock is worth vs. the current price.
FRC's fair value estimate for Anatara Lifesciences Ltd, and the rating behind it. ANR.AX last traded at AUD 0.01; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Anatara Lifesciences Ltd. Starting points for Anatara Lifesciences Ltd: EPS -AUD 0.0080, beta 0.70 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Anatara Lifesciences Ltd. Anatara Lifesciences Ltd does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Anatara Lifesciences Ltd. Trailing twelve-month EPS for Anatara Lifesciences Ltd stands at -AUD 0.0080. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Anatara Lifesciences Ltd. Anatara Lifesciences Ltd has reported as a listed company since 2014. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Anatara Lifesciences Ltd valued side by side against its closest peers. Anatara Lifesciences Ltd is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
Which funds and firms own the stock.
Which institutions hold Anatara Lifesciences Ltd, and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by Anatara Lifesciences Ltd executives and directors. Shares of Anatara Lifesciences Ltd have traded between AUD 0.0070 and AUD 0.02 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Anatara Lifesciences Ltd. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Anatara Lifesciences Ltd. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Anatara Lifesciences Ltd. Coverage tracks Anatara Lifesciences Ltd within Biotechnology (Healthcare). Press releases and market coverage, newest first.